Star Health share price today: returns, targets, key levels 2026

Latest reported share price levels

Star Health and Allied Insurance Company Ltd (NSE: STARHEALTH, BSE: 543412) has seen multiple price snapshots across dates in the data provided. The share price for STARHEALTH is listed as ₹588.65 as on 30 June 2026. Another live price snapshot shows ₹577.1, with the stock opening at ₹572 versus a previous close of ₹574, and moving between an intraday high of ₹584 and an intraday low of ₹569.

Separately, an update states the stock last traded at ₹474.40 after moving up 0.62% from a previous close of ₹471.50. And for an earlier date, the share price is shown as ₹459.15 as on 25 March 2026 (15:50 IST), when it opened at ₹455.10 versus a previous close of ₹455.50, with the day’s range reported as ₹453.75 to ₹465.55.

How the stock performed across periods

The dataset includes more than one set of return figures, indicating different snapshots and time stamps. One return set lists: past 1 week: 0.02%, past 1 month: 12.18%, past 3 months: 27.80%, past 6 months: 32.39%, past 1 year: 38.34%, past 3 years: 2.45%, and past 5 years: -35.52%.

Another return table reports: 1 day: 0.62%, 1 week: 11.58%, 1 month: 3.19%, 3 months: -4.05%, 1 year: 7.2%, and 3 years: -8.2% (5-year return marked N.A.). A separate line also mentions investment returns of roughly +10% over 1 month, +26.13% over 3 months, and +30.12% over 6 months, along with a +37.83% figure shown without a clearly visible period label.

Price action and key technical levels cited

The same live-price snapshot includes widely tracked moving averages. The 50-day moving average (DMA) is ₹524.94 and the 200-DMA is ₹486.49. The earlier March 2026 snapshot highlights a 52-week trading band at that time, with a low of ₹453.75 and a high of ₹465.55.

A separate market note reports a sharp single-day move: the stock ended 9% higher at ₹554 on the NSE, after hitting an intraday high of ₹577.60. The same note flags unusually high trading activity, with over 3 million shares traded on the NSE versus a three-month average of over 2 lakh shares.

Brokerages and analyst calls in the data

Brokerage commentary in the provided text points to a generally positive tilt, though with variation by house and time. One segment says 81% of analysts suggested investors can buy the stock, based on 21 analysts.

JM Financial is referenced twice in different contexts. One line says JM Financial prefers Star Health in the space, has a ‘Buy’ rating, and a target price of ₹650. Another report says JM Financial upgraded the stock to ‘Add’ from ‘Hold’ and raised its target price to ₹525.

Jefferies is also mentioned as maintaining a ‘Buy’ rating with a target price of ₹650. Another note mentions a view that retained an ‘Add’ recommendation with a target price of ₹463, which is described as below the then-current market level.

Shareholding and the Jhunjhunwala association

Star Health is described as a key portfolio holding for investor Rekha Jhunjhunwala in one of the reports. A specific update says Rekha Jhunjhunwala upped promoter stake by 1,253 bps to 15.57% in the December quarter.

Another part of the text states Rekha Jhunjhunwala, along with late investor Rakesh Jhunjhunwala, together held a 17.14% stake in Star Health as of the September quarter. A separate market note adds that the Jhunjhunwala entities are part of the promoter group and hold over 17% stake.

Quarterly performance and claims ratio metrics cited

Operational metrics referenced in the reports include a claims or loss ratio improvement. One report states the insurer’s claims ratio improved by 130 basis points year-on-year to 71.5% in the September quarter, aligning with estimates. Jefferies is also cited noting a loss ratio of 71.5%, improved by 130 bps YoY.

A separate note ties a sharp stock move to improved profitability: the company reported a profit of ₹210 crore for the December quarter compared with a loss of ₹578 crore a year earlier.

Market capitalisation and valuation snapshot in the text

The data includes multiple market-cap figures at different times. One line states the market cap was ₹33,915 crore as on 29 June 2026 (05:41). Another table lists Market Cap: ₹29,100 crore, along with ROE: 9.08%, P/E (TTM): 49.39, EPS (TTM): 10.02, P/B: 4.12, Dividend yield: 0.00%, Industry P/E: 19.23, and Book value: 120.05.

There is also a line that describes Star Health as having a ₹25,000 crore market cap and being the largest standalone health insurer in the country, indicating another point-in-time reference.

Key facts table

Market impact: what the numbers signal

The data points show how quickly sentiment can shift for the stock, with a reported 9% single-day rise to ₹554 on high delivery-based buying and trading volumes far above the recent average. The presence of multiple, sometimes conflicting return snapshots suggests the importance of checking the specific time window and timestamp when evaluating performance.

Brokerage targets ranging from ₹463 to ₹650 show that analyst expectations are not uniform, even when several firms carry ‘Buy’ or ‘Add’ recommendations. Operational metrics, such as the 71.5% claims ratio with a 130 bps YoY improvement, and the swing to a ₹210 crore profit in the December quarter from a ₹578 crore loss a year earlier, are the main quantified business drivers cited alongside the market moves.

Analysis: why this matters for investors tracking STARHEALTH

For investors, the immediate takeaway from the provided information is that STARHEALTH’s price action has been linked to both technical factors, such as moving averages and volume spikes, and fundamental markers like profitability and claims experience. The improvement in reported quarterly profitability and the cited claims ratio trend can influence how the market prices underwriting discipline in a health insurer.

At the same time, the valuation snapshot listed (including P/E 49.39 and P/B 4.12) provides context for how the stock is being priced relative to its book value and earnings at that point in time. The promoter-group holding references, including the 15.57% figure in one update and 17.14% as of the September quarter in another, remain a closely watched datapoint because changes in such stakes often draw market attention.

Conclusion

Star Health’s reported price points range from the mid-₹450s in March 2026 snapshots to ₹588.65 as on 30 June 2026, alongside a live quote near ₹577.1 in the dataset. Returns, market cap, and analyst targets vary across time-stamped updates, but the quantified operational positives cited include a 71.5% claims ratio in the September quarter and a ₹210 crore December-quarter profit versus a ₹578 crore loss a year earlier. The next meaningful signals for the stock, based on the themes in the data, will come from subsequent quarterly results, updated analyst notes, and fresh market-cap and volume trends tied to new disclosures.